All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: KRP114V
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Results from the 40-week EMPOWUR extension to the 12-week EMPOWUR trial shows that 75 mg of vibegron was well tolerated over the total exposure of 52 weeks with numerically greater improvements from baseline, compared to tolterodine across QoL and responder efficacy endpoints.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: RVT-901
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sumitovant Biopharma
Deal Size: $1,265.0 million Upfront Cash: Undisclosed
Deal Type: Merger November 12, 2020
Details:
The merger may enable Urovant's team to fully concentrate on the important task of preparing for its potential commercial launch of vibegron, the first new branded prescription drug for the treatment of OAB in nearly a decade.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: RVT-901
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Urovant Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020
Details:
Under the terms of the agreement, Sunovion will deploy its multi-specialty sales force to bring vibegron to primary care physicians (PCP). In support of this effort, Sunovion will provide sales and marketing activities targeting the PCP segment through March 31, 2026.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sumitovant Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 19, 2020
Details:
The exclusive three-year distribution agreement with aims to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron,Tolterodine Tartrate
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
Urovant Sciences a family company of Sumitovant announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two Phase 1 trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
52-week post hoc analysis shows Vibegron patients had statistically significant, sustained reduction in UUI and total incontinence episodes compared to active control.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2020
Details:
The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
